8 research outputs found
<i>Nfatc2</i> KO mice, but not <i>Tob1</i> KO mice show age-related accumulation of memory T cells.
<p>(A) Spleen and lymph node cells were isolated from age-matched WT, <i>Nfatc2</i> KO, and <i>Tob1</i> KO mice, and cells from each genotype and for each organ were pooled for experiments. Expression of CD44 and CD62L was measured by conventional cell surface staining in WT, <i>Nfatc2</i> KO, and <i>Tob1</i> KO T cells immediately after isolation from spleens or lymph nodes. Panels are representative two-dimensional contour plots showing CD44 and CD62L staining from young (top) and old (bottom) mice gated on CD3 T cells from representative mice as indicated. Similar data for young and old mice were obtained in 9 and 4 experiments using WT cells, 6 and 4 experiments using <i>Nfatc2</i> KO cells, and 4 and 4 experiments using <i>Tob1</i> KO cells, respectively. Means ± SD are provided in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100629#pone-0100629-t001" target="_blank">Table 1</a>.</p
<i>Nfatc2</i> deficiency leads to enhanced proliferation in a lymphodepleted environment of homeostatic expansion, but does not provide improved survival fitness in a competitive lymphoreplete environment.
<p>CD4<sup>+</sup>CD25<sup>−</sup> Tconvs were prepared as described from WT and from <i>Nfatc2</i> KO mice. Sorted cells (100,000) were adoptively transferred into the tail vein of two B6.SCID (top) or two B6.CD45.1 (bottom) mice. Recipients were sacrificed 15 days later and total cell numbers recovered from spleens (SP) and lymph nodes (LN) were enumerated using a CellDyn 3500 hematology analyzer. The percent of donor cells in each recipient was then calculated based on the percent of CD4<sup>+</sup>CD45.2<sup>+</sup> cells present in each preparation, and is represented by a symbol in the graphs. Lines indicate the mean for each recipient group.</p
Naïve T cells from <i>Nfatc2</i> KO mice show the hyper-proliferative response phenotype.
<p>CD4 T cells were isolated from single cell suspensions of spleens and lymph nodes from WT and <i>Nfatc2</i> KO littermates by negative immunomagnetic selection. CD4<sup>+</sup>CD25<sup>−</sup>CD44<sup>dim</sup> (naïve Tconv) cells were enriched by sorting to deplete CD4<sup>+</sup>CD25<sup>+</sup> (Treg) and CD4<sup>+</sup>CD44<sup>bright</sup> (memory) cells. Naïve Tconv cells were labeled with CFSE, mixed 1∶1 with syngeneic AgPCs and stimulated with anti-CD3. Proliferation was measured by CFSE dilution in CD4 T cells using flow cytometry after of 96 hr of culture. (A) Representative one-dimensional histograms of CFSE dilution from unstimulated (top) or from stimulated (bottom) WT and <i>Nfatc2</i> KO cells. Insets show two-dimensional contour plots of CD4 (y-axis) and CD44 (x-axis) expression. The box indicates the percent of CD4<sup>+</sup>CD44<sup>+</sup> cells at the end of the culture period. (B) Means ± S.D. of the percent of cells in triplicate samples that underwent 0–7 divisions over 96 hr for each genotype from 2 experiments for each genotype.</p
<i>Nfatc2</i> and <i>Tob1</i> KOs lead to hyper-proliferative T-cell responses <i>in vitro</i>.
<p>CD4 T cells were isolated from single cell suspensions of spleens and lymph nodes of age-matched WT, <i>Nfatc2</i> KO, and <i>Tob1</i> KO mice by negative immunomagnetic selection. CD4<sup>+</sup>CD25<sup>−</sup> (Tconv) cells were then enriched by depletion of CD4<sup>+</sup>CD25<sup>+</sup> (Treg) cells and labeled with CFSE. Tconv cells were mixed 1∶1 with syngeneic CD19<sup>+</sup> spleen cells (AgPCs) and stimulated with anti-CD3 (1 ng/ml). Proliferation was measured by CFSE dilution in CD4 T cells using flow cytometry after of 96 hr of culture. (A) Representative one-dimensional histograms of CFSE dilution from unstimulated (top) or from stimulated (bottom) WT, <i>Nfatc2</i> KO and <i>Tob1</i> KO T cells from one experiment using pooled spleen cells from 3 mice each. (B) Means ± S.D. of the percent of cells that underwent 0–7 divisions over 96 hr for each genotype. The data summarize 8, 4, and 3 experiments using triplicate samples of WT cells, <i>Nfatc2</i> KO cells, and <i>Tob1</i> KO cells, respectively, each with pooled cells from 2 or 3 mice.</p
T cell expansion in <i>Nfatc2</i> and <i>Tob1</i> KO mice is not due to Treg dysfunction.
<p>CD4 T cells were isolated from single cell suspensions of spleens and lymph nodes from age-matched WT, <i>Nfatc2</i> KO, and <i>Tob1</i> KO mice by negative immunomagnetic selection. CD4<sup>+</sup>CD25<sup>−</sup> (Tconv) cells and CD4<sup>+</sup>CD25<sup>+</sup> (Tregs) were enriched by sorting. Tconv cells were labeled with CFSE and Treg cells were labeled with PKH26. Tconvs (100,000/well) were then mixed 1∶1 with syngeneic AgPCs and stimulated with anti-CD3 in the presence of absence of 50,000 Treg cells as indicated. Proliferation was measured by CFSE dilution in CD4 T cells using flow cytometry after of 96 hr of culture. (A) Expression of CD4, CD25, and CTLA-4 was assessed by conventional cell surface staining; expression of Foxp3 was examined by intracellular staining Panels are representative two-dimensional contour plots showing CD4 and CD25 staining from WT, <i>Nfatc2</i> KO, and <i>Tob1</i> KO mice gated on CD3 T cells. Boxed areas represent CD4<sup>+</sup>CD25<sup>+</sup> (Treg) cells and CD4<sup>+</sup>CD25<sup>−</sup> (Tconv) cells. Small panels to the right represent two-dimensional contour plots showing CTLA-4 and Foxp3 staining, respectively for Tregs on top and Tconvs below. (B) Representative one-dimensional histograms of CFSE dilution from stimulated WT cells. Small panels to the right represent one-dimensional histograms of CFSE dilution for the same WT cells, respectively with the addition of WT Tregs, <i>Nfatc2</i> KO Tregs, <i>Tob1</i> KO Tregs, or WT Tregs treated with CsA as indicated. (C) Means ± S.D. of the percent of cells that underwent 0–7 divisions over 96 hr for each genotype with and without Tregs. The data summarize 8 experiments using WT Tregs, 4 experiments using <i>Nfatc2</i> KO Tregs, 2 experiments using <i>Tob1</i> KO Tregs, and 2 experiments using WT Tregs treated with CsA, each with pooled cells from 2 or 3 mice. The number of WT Tconv cells that did not undergo cell division was significantly greater (p<0.01), and the number of cells undergoing 2 or more divisions was significantly reduced (p<0.0001) when <i>Tob1</i> KO Tregs were present in the culture than when WT Tregs or <i>Nfatc2</i> KO Tregs were present in the culture.</p
<i>Nfatc2</i> and <i>Tob1</i> KO mice have increased numbers of persistently activated cells <i>in vivo</i>.
<p>Spleen and lymph node cells were isolated from age-matched WT, <i>Nfatc2</i> KO, and <i>Tob1</i> KO mice, and cells from each genotype and for each organ were pooled for experiments. Expression of CDK4 was measured by intracellular staining and expression of CD69 was measured by conventional cell surface staining of freshly isolated cells. (A). One-dimensional histograms (top) showing CDK4 expression, gated on CD4 and CD8 cells from representative <i>Nfatc2</i> KO and <i>Tob1</i> KO mice overlaid on WT controls as indicated. Dark lines in the histograms represent KOs and grey lines represent WT mice. Bar graphs (bottom) represent means ± SD of the mean fluorescence intensity (MFI) for CDK4 expression in CD4 and CD8 cells. Data summarize 15, 12, and 5 experiments using triplicate samples of WT cells, <i>Nfatc2</i> KO cells, <i>Tob1</i> KO cells, respectively, each with pooled cells from 2 or 3 mice. MFIs among different experiments showed normal distribution. Asterisks denote values that are significantly different from WT (Student t-test p<0.05). (B) One-dimensional histograms (top) showing CD69 expression, gated on CD4 and CD8 cells from representative young (left) and old (right) <i>Nfatc2</i> KO and <i>Tob1</i> KO mice overlaid on WT controls as indicated. Dark lines in the histograms represent KOs and grey lines represent WT mice. Bar graphs (bottom) represent means ± SD percent CD69<sup>+</sup> cells in the CD4 and CD8 compartments. Data for young and old mice summarize 10 and 4 experiments using triplicate samples of WT cells, 6 and 8 experiments using triplicate samples of <i>Nfatc2</i> KO cells, and 4 and 3 experiments using triplicate samples of <i>Tob1</i> KO cells, respectively. The percent of positive cells among different experiments showed normal distribution. Asterisks denote values that are significantly different from WT (Student t-test p<0.05).</p
Lymphocytic infiltrates into parenchymal organs and B-cell malignancies in <i>Nfatc2</i> KO mice.
<p>(A) Photomicrograph of a representative section from the parotid salivary gland of a 21-month old <i>Nfatc2</i> KO mouse stained with H&E (magnification 100X) showing mild to moderate lymphocytic aggregates in the interstitium. Approximately 70% of the infiltrate consisted of B cells. (B) Photomicrograph of a representative section from lymph node of a 20-month old <i>Nfatc2</i> KO mice stained with H&E (magnification 400X) showing effacement with corticomedullary architecture expanded by a homogenous population of large lymphocytes with large eccentric nuclei containing open to marginated chromatin, single to multiple prominent nucleoli, and scant to moderate amphophilic cytoplasm. The section contains scattered necrotic cells and 0–2 mitoses per high power field. The histological appearance is consistent with plasmablastic plasmacytoma. Similar tumors were identified in lymph nodes, livers, and spleens of <i>Nfatc2</i> KO mice. (C and D) Immunohistochemical staining using antibodies against B220 (C) and CD3 (D) in serial sections from (B), showing the tumor is comprised by a monotonous population of malignant B cells with few residual T cells.</p
An Anti-B7-H4 Antibody–Drug Conjugate for the Treatment of Breast Cancer
B7-H4
has been implicated in cancers of the female reproductive system and
investigated for its possible use as a biomarker for cancer, but there
are no preclinical studies to demonstrate that B7-H4 is a molecular
target for therapeutic intervention of cancer. We provide evidence
that the prevalence and expression levels of B7-H4 are high in different
subtypes of breast cancer and that only a few normal tissues express
B7-H4 on the cell membrane. These profiles of low normal expression
and upregulation in cancer provide an opportunity for the use of antibody–drug
conjugates (ADCs), cytotoxic drugs chemically linked to antibodies,
for the treatment of B7-H4 positive cancers. We have developed an
ADC specific to B7-H4 that uses a linker drug consisting of a potent
antimitotic, monomethyl auristatin E (MMAE), linked to engineered
cysteines (THIOMAB) via a protease labile linker. We will refer to
ADCs that use the THIOMAB format as TDCs to help distinguish the
format from standard MC-vc-MMAE ADCs that are conjugated to the interchain
disulfide bonds. Anti-B7-H4 (h1D11)-MC-vc-PAB-MMAE (h1D11 TDC) produced
durable tumor regression in cell line and patient-derived xenograft
models of triple-negative breast cancer. It also binds rat B7-H4 with
similar affinity to human and allowed us to test for target dependent
toxicity in rats. We found that our anti-B7-H4 TDC has toxicity findings
similar to untargeted TDC. Our results validate B7-H4 as an ADC target
for breast cancer and support the possible use of this TDC in the
treatment of B7-H4<sup>+</sup> breast cancer